*Selenoneine ameliorates peroxide-induced oxidative
stress in C. elegans*

Isabelle Rohn^a, Nina Kroepfl^b, Michael Aschner^c, Julia Bornhorst^{a,d,e}, Doris Kuehnelt^b, Tanja
Schwerdtle^{a,d,*}

^a Department of Food Chemistry, Institute of Nutritional Science, University of Potsdam,
Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany

^b Department of Analytical Chemistry, Institute of Chemistry, NAWI Graz, University of
Graz, Universitaetsplatz 1, 8010 Graz, Austria

^c Department of Molecular Pharmacology, Neuroscience, and Pediatrics, Albert Einstein
College of Medicine, 1300 Morris Park Avenue, 10461 Bronx, NY, USA

^d TraceAge – DFG Research Unit FOR 2558, Berlin-Potsdam-Jena, Germany

^e Food Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal,
Gaußstraße 20, 42119 Wuppertal, Germany

author e-mail addresses:

isabelle.rohn@uni-potsdam.de, nina.kroepfl@uni-graz.at, michael.aschner@einstein.yu.edu,
julia.bornhorst@uni-potsdam.de, doris.kuehnelt@uni-graz.at, tanja.schwerdtle@uni-
potsdam.de

* Corresponding author address:

Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee 114-116,
14558 Nuthetal, Germany, Phone: +49-33200/88-5580, Fax: +49-33200/88-5573, e-mail:
tanja.schwerdtle@uni-potsdam.de

Abstract

Scope: Selenoneine (2-selenyl- N_α , N_α , N_α -trimethyl-L-histidine), the selenium (Se) analogue of the ubiquitous thiol compound and putative antioxidant ergothioneine, is the major organic selenium (Se) species in marine fish. Although its antioxidant efficacy has been proposed, selenoneine has been poorly characterized, preventing conclusions on its possible beneficial health effects.

Methods and results: Treatment of *Caenorhabditis elegans* (*C. elegans*) with selenoneine for 18 h attenuated the induction of reactive oxygen and nitrogen species (RONS). However, the effect was not immediate, occurring 48 h post-treatment. Total Se and Se speciation analysis revealed that selenoneine was efficiently taken up and present in its original form directly after treatment, with no metabolic transformations observed. 48 h post-treatment, total Se in worms was slightly higher compared to controls and no selenoneine could be detected.

Conclusion: The protective effect of selenoneine may not be attributed to the presence of the compound itself, but rather to the activation of molecular mechanisms with consequences at more protracted time points.

Keywords

Selenoneine / *Caenorhabditis elegans* / selenium / oxidative stress

Abbreviations

C. elegans, *Caenorhabditis elegans*; **ESI-Orbitrap-MS**, electrospray ionization orbitrap mass spectrometry; **ICP-MS**, inductively coupled plasma mass spectrometry; **MeSeCys**, methylselenocysteine; **OCTN-1**, organic cation / carnitine transporter 1; **QQQ**, triple quadrupole; **RONS**, reactive oxygen and nitrogen species; **RP-HPLC**, reversed phase high performance liquid chromatography; **SeMet**, selenomethionine, **t-BOOH**, *tert*-butyl-hydroperoxide

Short communication

Selenoneine (2-selenyl-N_α, N_α, N_α-trimethyl-L-histidine) is the predominant form of organic selenium (Se) in tuna, swordfish and other marine fish species [1-3]. Being the Se analogue of ergothioneine, a sulfur-containing putative antioxidant [4] it has attracted considerable attention and similar beneficial properties have been attributed to selenoneine. However, data are still insufficient. In an *in vitro* radical scavenging assay, selenoneine was more effective as compared to ergothioneine towards 1,1-diphenyl-2-picrylhydrazyl [1]. It was also hypothesized to bind to heme proteins, preventing iron auto-oxidation [1,5]. Moreover, a reduction of methylmercury (MeHg) accumulation and toxicity in zebrafish embryos was reported in the presence of selenoneine [6]. The proposed mechanism of detoxification was posited to involve the formation of selenoneine-MeHg complexes and their excretion *via* the ergothioneine transporter OCTN-1, which was also discussed in dolphin liver [7]. Recently, feeding a selenoneine-containing tuna extract was shown to reduce the pathology of experimental colorectal cancers in mice, and the authors suggested this extract 'might be effective as a dietary antioxidant' [8]. The detection of selenoneine and its methylated derivative Se-methyl-selenoneine in human blood and urine demonstrates its bioavailability and putative metabolism in humans [9-11]. However, the pure compound has yet to be assessed *in vivo*, and the interplay between bioavailability, metabolism and possible protective effects, as well as underlying mechanisms have yet to be deciphered.

In the present study, we addressed these endpoints in the well-characterized *in vivo* model *Caenorhabditis elegans* (*C. elegans*). The nematode provides many intrinsic advantages as an alternative and complementary model organism, including an invariant and fully described developmental program and a high degree of evolutionarily conserved genes and signaling pathways [12]. Moreover, its rapid life cycle allows studying effects during the course of the worms' development with minimum effort. Recently, immediate and sustained effects of selenomethionine (SeMet), methylselenocysteine (MeSeCys) and selenite on the antioxidant defense system have been studied in *C. elegans*, and their protective efficacy towards chemically-induced formation of reactive oxygen and nitrogen species (RONS) has been demonstrated [13]. Based on the previously established experimental design [13], synchronized wildtype *C. elegans* (N2, *Caenorhabditis* Genetics Center, Minneapolis, USA) were exposed to selenoneine for 18 h during hatching. Subsequent endpoint analysis was conducted either directly post-treatment in L1 larvae, or 48 h post-treatment in worms grown to L4 stage without additional selenoneine exposure to investigate possible sustained effects. Selenoneine was isolated and purified in its dimeric form (Fig. 1) from genetically modified yeast *Schizosaccharomyces pombe* as described elsewhere [14]. Stock solutions (10 mM) were prepared in purified water, stored at -80 °C and diluted shortly before each use. Eggs

1 were hatched in M9 buffer supplied with 1 or 10 μM selenoneine, or M9 buffer only. Although
2 in the previous study, 100 μM of the Se species were used, the lower concentrations were
3 chosen to mimic an exposure scenario that is closer to the physiological situation, with respect
4 to uptake and respective exposure scenarios.

5 Following incubation, L1 stage larvae were exposed to *tert*-butyl-hydroperoxide (*t*-BOOH), and
6 RONS formation was measured in intact worms using the carboxy-DCFH-DA assay. This
7 assay was established and optimized regarding the applied *t*-BOOH and carboxy-DCFH-DA
8 concentrations for both L1 and L4 stage worms as extensively described in the previous study
9 [13]. Interestingly, immediately after selenoneine treatment, the extent of RONS induction was
10 indistinguishable between control worms and selenoneine-treated worms, hence, no protective
11 effect occurred at this time point (Fig. 2A). However, 48 h post-treatment, a pronounced, dose-
12 dependent attenuation of *t*-BOOH induced RONS formation was observed (Fig. 2B). The
13 absence of RONS-attenuating effects directly following incubation is in contrast to our previous
14 study, since the therein tested Se species effectively diminished *t*-BOOH induced RONS
15 formation immediately post-treatment, as well as 48 h post-treatment [13]. This discrepancy
16 may arise from the lower selenoneine concentrations applied here, as opposed to the 10- to
17 100-fold higher doses used previously, but might also be driven by the different Se species. In
18 general, L1 stage worms command a highly potent antioxidant defense system to protect the
19 developing nematodes, which are more vulnerable to exogenous stressors due to their
20 immature, penetrable cuticles. Therefore, a much higher *t*-BOOH concentration was necessary
21 to induce RONS in this early life stage as compared to L4 stage worms (L1 stage: 350 μM *t*-
22 BOOH, L4 stage: 50 μM *t*-BOOH; selenoneine provided at 1 and 10 μM). Given the fact that
23 the oxidant concentration was multiple times higher as compared to the applied selenoneine
24 concentrations, along with the powerful antioxidant system at base level, the selenoneine
25 treatment might be unable to contribute to any additional benefits at this developmental stage.
26 Interestingly, 48 h post-treatment, selenoneine was more effective in diminishing RONS levels
27 as compared to higher doses of other Se compounds. For instance, treatment with 1 μM
28 selenoneine attenuated RONS formation to a similar extent as 100 μM MeSeCys after 120 min,
29 and had an approximately 20 – 30% more pronounced quenching effect than 100 μM selenite
30 or SeMet [13]. Compared to the lower dose, 10 μM selenoneine was even more effective and
31 inhibited *t*-BOOH induced RONS formation almost completely.

32 In order to obtain mechanistic insights for the observed effects, we investigated the
33 bioavailability as well as the retention of selenoneine in the worms. Thus, total Se contents
34 were quantified immediately and 48 h post-treatment *via* isotope dilution ICP-QQQ-MS
35 following microwave-assisted acid digestion according to protocols published before [13]. As
36 shown by the dose-dependent increase in total Se at L1 stage, selenoneine was effectively
37 taken up by the worms (Table 1). In addition, to investigate if selenoneine is metabolized in

C. elegans, Se speciation analysis was carried out. Thus, worms were pelletized directly after or 48 h post-treatment, purified water was added to a total volume of 250 μ L, and lysates were obtained by sonication and centrifugation as previously described [15]. An aliquot was subjected to protein determination *via* the bicinchoninic acid (BCA) assay, and after a second centrifugation step (20 000 $\times$ g, 4 $^{\circ}$ C, 20 min), RP-HPLC-ICP-MS was performed according to a previously published method [16]. Se speciation analysis revealed that the major part of Se was present in the form of selenoneine at L1 stage (Table 1, Fig. 3A). The presence of selenoneine was confirmed by HPLC-ESI-Orbitrap-MS as described before [16], while no additional small organic Se species were detected. Hence, no indications of selenoneine metabolism were obtained. The difference between selenoneine and the total Se content (Table 1) might have been caused by the fact that due to the low amount of sample, total Se determination and Se speciation analysis were performed with different sets of specimens. Moreover, the missing Se might be bound or partially attached to proteins or peptides, thus requiring further investigation. 48 h post-treatment, total Se contents in worms hatched in the presence of selenoneine were only slightly higher compared to untreated controls (10 μ M vs. control: $p = 0.0510$), indicating that most of the ingested compound is excreted until L4 stage. Accordingly, selenoneine was neither detectable by RP-HPLC-ICP-MS (Table 1, Fig. 3B) nor by HPLC-ESI-Orbitrap-MS. Traces of an unknown Se species eluting right before selenoneine were detected, which was not present in control worms. However, its presence at concentrations below 1 μ g Se/L prevented its identification by HPLC-ESI-Orbitrap-MS. Moreover, trace quantities of a signal co-eluting with SeMet were detected at the L4 stage, but verification with molecular MS was again not possible. The putative SeMet was also found in control worms (Fig. A.1, Appendix), indicating that it might have been an integral part of proteins that was released in the course of sample preparation. It was previously shown that *C. elegans*, analogous to higher organisms, incorporate SeMet into proteins [13]. Altogether, both total Se contents and speciation data revealed that selenoneine was not retained in the worms 48 h post-treatment. Consequently, the protective effect against *t*-BOOH induced RONS formation is unlikely to be caused by the presence of the compound itself. Selenoneine has a more complex, bulkier structure as opposed to other Se species such as selenite, SeMet or MeSeCys. This might be a decisive factor in leading to the absence of protective effects immediately post-treatment. Possibly, the compound is taken up into cells more slowly and/or to a lesser extent compared to smaller Se species, and is mainly present in the worms' intestinal tract at this early time point. Apart from a delayed cellular uptake, differences in metabolism might play a role as well. The formation of highly reactive intermediates such as selenide or methylselenol is considered to be a central step in the activation of redox-active mechanisms by Se species [17]. In general, it is not known if selenoneine is metabolized *via* these intermediates at all, and moreover, if *C. elegans* would be capable of such metabolism.

To date, only Se-methylselenoneine has been identified as a putative metabolite of selenoneine in humans [10]. Here, neither Se-methylselenoneine nor any other potential metabolites have been identified following 18 h treatment. In contrast, a comprehensive metabolism of SeMet and MeSeCys was demonstrated after acute (30 min) high-dose exposure in *C. elegans* [15]. Nevertheless, the RONS-attenuating effect observed 48 h post-treatment indicates that selenoneine is not just shuttled through the worm's intestinal tract, but seems to get into the cells and trigger any molecular mechanism, thereby causing this delayed effect. In the previous study, treatment with the Se species had distinct effects on the Nrf2/Skn-1 and FoxO/Daf-16 stress response pathways at the mRNA level [13]. Therefore, the same genes were investigated in the present study. However, their expression levels were not affected by selenoneine, neither directly nor 48 h post-treatment (Fig. A.2, Appendix). Thus, there are no indications on an involvement of the investigated pathways in mediating selenoneine's effects. Elucidating the underlying mechanism clearly requires further studies, since knowledge on selenoneine's mode of action is a necessary attribute for consideration of any possible health benefits in the future. Ergothioneine, the sulfur analogue of selenoneine, has been shown to prevent intracellular RONS accumulation by inhibiting the p38-MAPK signaling cascade, which is activated by H₂O₂, in human neuronal cells [18]. Accordingly, exploring whether selenoneine affects the p38-MAPK pathway as well might be a promising approach.

Conclusion

In the present study, treatment of *C. elegans* with selenoneine did not diminish immediately chemically induced RONS formation, but 48 h post-treatment. Since Se analysis confirmed the uptake and presence of selenoneine after treatment, but failed to demonstrate its retention, the protective effect may not be explained by a radical-scavenging activity of selenoneine. With the experimental design used in this study, no indications for a direct scavenger function of selenoneine were obtained. Instead, the delayed protection might rather involve the activation of molecular signaling cascades. The underlying mechanism clearly requires further investigation, to better characterize selenoneine's protective effects in the future.

Declarations of interest

None.

Acknowledgements

This work was funded by the German Research Foundation (DFG), grant number SCHW 903/9-1, BO 4103/2-1 and the Austrian Science Fund (FWF), project number I 2262-N28, as well as the DFG Research Unit TraceAge (FOR 2558). MA was supported in part by grants from the National Institute of Environmental Health Sciences (NIEHS R01ES07331, NIEHS R01ES10563 and NIEHS R01ES020852).

References

- [1] Y. Yamashita, M. Yamashita, Identification of a novel Se-containing compound, selenoneine, as the predominant chemical form of organic Se in the blood of bluefin tuna, *J. Biol. Chem.* 285 (2010) 18134–8. doi:10.1074/jbc.C110.106377.
- [2] Y. Yamashita, H. Amlund, T. Suzuki, T. Hara, M. A. Hossain, T. Yabu, K. Touhata, M. Yamashita, Selenoneine, total Se, and total mercury content in the muscle of fishes, *Fish. Sci.* 77 (2011) 679–686. doi:10.1007/s12562-011-0360-9.
- [3] N. Kroepfl, K. B. Jensen, K. A. Francesconi, D. Kuehnelt, Human excretory products of Se are natural constituents of marine fish muscle, *Anal. Bioanal. Chem.* 407 (2015) 7713–9. doi:10.1007/s00216-015-8936-3.
- [4] I. K. Cheah, B. Halliwell, Ergothioneine; antioxidant potential, physiological function and role in disease, *Biochim. Biophys. Acta* 1822 (2012) 784–93. doi:10.1016/j.bbadis.2011.09.017.
- [5] Y. Yamashita, Discovery of the strong antioxidant selenoneine in tuna and Se redox metabolism, *World J. Biol. Chem.* 1 (2010) 144–50. doi:10.4331/wjbc.v1.i5.144.
- [6] M. Yamashita, Y. Yamashita, T. Suzuki, Y. Kani, N. Mizusawa, S. Imamura, K. Takemoto, T. Hara, M. A. Hossain, T. Yabu, K. Touhata, Selenoneine, a Novel Se-Containing Compound, Mediates Detoxification Mechanisms against Methylmercury Accumulation and Toxicity in Zebrafish Embryo, *Mar. Biotechnol.* 15 (2013) 559–70. doi:10.1007/s10126-013-9508-1.
- [7] Z. P. Zayas, L. Ouerdane, S. Mounicou, R. Lobinski, M. Monperrus, D. Amouroux, Hemoglobin as a major binding protein for methylmercury in white-sided dolphin liver, *Anal. Bioanal. Chem.* 406 (2014), 1121–9. doi:10.1007/s00216-013-7274-6.
- [8] J. Masuda, C. Umemura, M. Yokozawa, K. Yamauchi, T. Seko, M. Yamashita, Y. Yamashita, Dietary Supplementation of Selenoneine-Containing Tuna Dark Muscle Extract Effectively Reduces Pathology of Experimental Colorectal Cancers in Mice, *Nutrients* 10 (2018) E1380. doi:10.3390/nu10101380.
- [9] M. Yamashita, Y. Yamashita, T. Ando, J. Wakamiya, S. Akiba, Identification and determination of selenoneine, 2-Selenyl-N_α, N_α, N_α-Trimethyl-L-histidine, as the major

- organic Se in blood cells in a fish-eating population on remote Japanese Islands, Biol. Trace Elem. Res. 156 (2013) 36–44. doi:10.1007/s12011-013-9846-x.
- [10] M. Klein, L. Ouerdane, M. Bueno, F. Pannier, Identification in human urine and blood of a novel Se metabolite, Se-methylselenoneine, a potential biomarker of metabolism in mammals of the naturally occurring selenoneine, by HPLC coupled to electrospray hybrid linear ion trap-orbital ion trap MS, Metallomics 3 (2011) 513–20. doi:10.1039/c0mt00060d.
- [11] N. Kroepfl, K. A. Francesconi, T. Schwerdtle, D. Kuehnelt, Selenoneine and ergothioneine in human blood cells determined simultaneously by HPLC/ICP-QQQ-MS, J. Anal. At. Spectrom. 34 (2019) 127–34. doi:10.1039/C8JA00276B.
- [12] M. C. K. Leung, P. L. Williams, A. Benedetto, C. Au, K. J. Helmcke, M. Aschner, J. N. Meyer, *Caenorhabditis elegans*: An Emerging Model in Biomedical and Environmental Toxicology, Toxicol. Sci. 106 (2008) 5–28. doi:10.1093/toxsci/kfn121.
- [13] I. Rohn, S. Raschke, M. Aschner, S. Tuck, D. Kuehnelt, A. Kipp, T. Schwerdtle, J. Bornhorst, Treatment of *Caenorhabditis elegans* with Small Se Species Enhances Antioxidant Defense Systems, Mol. Nutr. Food Res. (2019) e1801304. doi:10.1002/mnfr.201801304.
- [14] N. G. Turrini, N. Kroepfl, K. B. Jensen, T. C. Reiter, K. A. Francesconi, T. Schwerdtle, W. Kroutil, D. Kuehnelt, Biosynthesis and isolation of selenoneine from genetically modified fission yeast, Metallomics 10 (2018) 1532–38. doi:10.1039/C8MT00200B.
- [15] I. Rohn, T. A. Marschall, N. Kroepfl, K. B. Jensen, M. Aschner, S. Tuck, D. Kuehnelt, T. Schwerdtle, J. Bornhorst, Selenium species-dependent toxicity, bioavailability and metabolic transformations in *Caenorhabditis elegans*, Metallomics 10 (2018) 818–27. <https://doi.org/10.1039/c8mt00066b>.
- [16] I. Rohn, N. Kroepfl, J. Bornhorst, D. Kuehnelt, T. Schwerdtle, Side-directed transfer and presystemic metabolism of selenoneine in a human intestinal barrier model, Mol. Nutr. Food Res. (2019) e1900080. doi: 10.1002/mnfr.201900080.
- [17] C.M. Weekley, H. H. Harris, Which form is that? the importance of selenium speciation and metabolism in the prevention and treatment of disease. Chem. Soc. Rev. 42 (2013) 8870–94. <https://doi.org/10.1039/c3cs60272a>.
- [18] R. Colognato, I. Laurenza, I. Fontana, F. Coppedé, G. Siciliano, S. Coecke, O. I. Aruoma, L. Benzi, L. Migliore, Modulation of hydrogen peroxide-induced DNA damage, MAPKs activation and cell death in PC12 by ergothioneine, Clin. Nutr. 25 (2006) 135–45. doi:10.1016/j.clnu.2005.10.005.

Figure legends

Figure 1. Chemical structures of selenoneine in its reduced monomeric form as well as its oxidized dimeric form.

Figure 2. RONS induction by *tert*-butyl-hydroperoxide (*t*-BOOH) following exposure to selenoneine for 18 h during hatching measured after dye loading and subsequent treatment with 350 μ M (L1) or 50 μ M (L4) *t*-BOOH. Data were normalized to the corresponding negative control (w/o *t*-BOOH) of each hatch treatment group. Shown are mean values of at least two independent experiments measured in triplicate wells + SEM. Statistical analysis by two-way ANOVA, followed by Dunnett's *post hoc* test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. control. (A) L1 stage. (B) L4 stage (48 h post-treatment). Mean fluorescence intensity of control worms (w/o *t*-BOOH) after 3 min: 3000 units at L1 stage, 7000 units at L4 stage.

1: control, 1 μ M selenoneine, 10 μ M selenoneine.

Table 1. Total selenium (Se) and selenoneine contents of *C. elegans* following hatch incubation (18 h) with selenoneine, directly after treatment (L1 stage, 0 h) and 48 h post-treatment (L4 stage). Shown are values of at least two independent experiments.

Figure 3. RP-HPLC-ICP-MS elution profiles of *C. elegans* lysates following hatch incubation (18 h) with 10 μ M selenoneine, (A) directly after treatment or (B) 48 h post-treatment; column: Atlantis dC18 (4.6 x 150 mm), 20 mM ammonium formate 0.1 mM TCEP 3% MeOH pH 3; 1 mL/min; injection volume: 10 μ L.

Table 1: Total selenium (Se) and selenoneine contents of *C. elegans* following hatch incubation (18 h) with selenoneine, directly after treatment (L1 stage, 0 h) and 48 h post-treatment (L4 stage). Shown are values of at least two independent experiments.

0 h post-treatment (L1 stage)			48 h post-treatment (L4 stage)	
Applied concentration	ng Se/mg protein (<i>x-fold of control</i> ^a)	ng selenoneine/mg protein	ng Se/mg protein (<i>x-fold of control</i> ^b)	Selenoneine [μg selenoneine/L]
1 μM	4.0 – 4.3 (4.5 – 4.7 <i>x</i>)	1.4 – 2.3	1.3 – 1.8 (1.1 – 1.5 <i>x</i>)	< 1
10 μM	33.2 – 33.9 (36.9 – 37.7 <i>x</i>)	13.8 – 25.6	1.7 – 2.2 (1.4 – 1.9 <i>x</i>)	< 1

^a 0.8 – 1.0 ng Se/mg protein (L1 stage), ^b 0.9 – 1.4 ng Se/mg protein (L4 stage)

Figure 1. Chemical structures of selenoneine in its reduced monomeric form as well as its oxidized dimeric form.

Figure 2. RONS induction by *tert*-butyl-hydroperoxide (*t*-BOOH) following exposure to selenoneine for 18 h during hatching measured after dye loading and subsequent treatment with 350 µM (L1) or 50 µM (L4) *t*-BOOH. Data were normalized to the corresponding negative control (w/o *t*-BOOH) of each hatch treatment group. Shown are mean values of at least two independent experiments measured in triplicate wells + SEM. Statistical analysis by two-way ANOVA, followed by Dunnett's *post hoc* test: *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. (A) L1 stage. (B) L4 stage (48 h post-treatment). Mean fluorescence intensity of control worms (w/o *t*-BOOH) after 3 min: 3000 units at L1 stage, 7000 units at L4 stage.

1 ● control, 1 µM   2 ● selenoneine, 10 µM   3 ● selenoneine.

1

2 Figure 3. RP-HPLC-ICP-MS elution profiles of *C. elegans* lysates following hatch incubation (18 h) with 10 μ M
 3 selenoneine, (A) directly after treatment or (B) 48 h post-treatment; column: Atlantis dC18 (4.6 x 150 mm), 20
 4 mM ammonium formate 0.1 mM TCEP 3% MeOH pH 3; 1 mL/min; injection volume: 10 μ L.